Biotech

All Articles

Pfizer takes $230M hit after axing fell short DMD genetics therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) genetics treatment failure has actually blown a ...

AC Immune sees 'spots' possible in Alzheimer's medication records

.After greater than 20 years of work with neurodegenerative health conditions, Swiss biotech air con...

GSK falls ph. 2 HPV vaccination over lack of best-in-class prospective

.GSK has actually junked a phase 2 individual papillomavirus (HPV) injection from its own pipe after...

OS Treatments refiles $6M IPO to cash HER2 medication, preclinical ADCs

.OS Therapies will certainly provide on the NYSE American inventory substitution today using a $6.4 ...

ALX's fizzling CD47 response fee sends out supply spiraling down

.ALX Oncology's period 2 stomach cancer response rate has compromised. After seeing its own CD47 blo...

Ionis axes eye ailment from targets of Roche-partnered possibility after data disappoint

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has actually disappointed assumptions...

Biogen's CEO claimed no high-risk deals in 2023. He prepares to be daring

.While Biogen's pharma peers are actually hunting for late-stage assets with little bit of danger, c...

Instil refills pipe in $2B biobucks deal with ImmunOnco

.Instil Biography has actually been actually a biotech seeking a pipeline after it ditched its lead ...

Biogen leaves Denali Alzheimer's collab

.Biogen has returned rights to an early Alzheimer's condition system to Denali Therapies, going out ...

Takeda faucets brand new mind people oncology business-- Chutes &amp Ladders

.Invite to today's Chutes &amp Ladders, our summary of considerable management hirings, firings and ...